HRP20100326T1 - 2-aminoariloksazolni spojevi kao inhibitori tirozinske kinaze - Google Patents
2-aminoariloksazolni spojevi kao inhibitori tirozinske kinaze Download PDFInfo
- Publication number
- HRP20100326T1 HRP20100326T1 HR20100326T HRP20100326T HRP20100326T1 HR P20100326 T1 HRP20100326 T1 HR P20100326T1 HR 20100326 T HR20100326 T HR 20100326T HR P20100326 T HRP20100326 T HR P20100326T HR P20100326 T1 HRP20100326 T1 HR P20100326T1
- Authority
- HR
- Croatia
- Prior art keywords
- oxazol
- phenyl
- methyl
- pyridin
- ylamino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 21
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 3
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 40
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 229910052794 bromium Inorganic materials 0.000 claims 23
- 229910052801 chlorine Inorganic materials 0.000 claims 23
- 229910052731 fluorine Inorganic materials 0.000 claims 23
- 229910052740 iodine Inorganic materials 0.000 claims 23
- 125000005843 halogen group Chemical group 0.000 claims 17
- -1 nitro, formyl Chemical group 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000004432 carbon atom Chemical group C* 0.000 claims 13
- 125000005842 heteroatom Chemical group 0.000 claims 13
- 229910052757 nitrogen Inorganic materials 0.000 claims 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 13
- 125000004430 oxygen atom Chemical group O* 0.000 claims 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000003277 amino group Chemical group 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 206010025135 lupus erythematosus Diseases 0.000 claims 3
- 125000002971 oxazolyl group Chemical group 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 3
- 229910052705 radium Inorganic materials 0.000 claims 3
- 229910052701 rubidium Inorganic materials 0.000 claims 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 229910003827 NRaRb Inorganic materials 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 150000001540 azides Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 201000003068 rheumatic fever Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- YJTHDZOOFLIDAH-UHFFFAOYSA-N 1-(2-fluorophenyl)-3-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]urea Chemical compound C1=C(NC=2OC(=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)NC1=CC=CC=C1F YJTHDZOOFLIDAH-UHFFFAOYSA-N 0.000 claims 1
- LLKMLSXETYSLPE-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]urea Chemical compound C1=C(NC=2OC(=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)NC1=CC=C(Cl)C=C1 LLKMLSXETYSLPE-UHFFFAOYSA-N 0.000 claims 1
- BGQHVFBHLADCQZ-UHFFFAOYSA-N 1-(4-cyanophenyl)-3-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]thiourea Chemical compound C1=C(NC=2OC(=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=S)NC1=CC=C(C#N)C=C1 BGQHVFBHLADCQZ-UHFFFAOYSA-N 0.000 claims 1
- BAVXBJWGPLEKED-UHFFFAOYSA-N 1-(4-cyanophenyl)-3-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]urea Chemical compound C1=C(NC=2OC(=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)NC1=CC=C(C#N)C=C1 BAVXBJWGPLEKED-UHFFFAOYSA-N 0.000 claims 1
- PLQYBDZYCAXEDV-UHFFFAOYSA-N 1-(4-cyanophenyl)-3-[4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]thiourea Chemical compound C1=C(NC=2OC(=CN=2)C=2C=CN=CC=2)C(C)=CC=C1NC(=S)NC1=CC=C(C#N)C=C1 PLQYBDZYCAXEDV-UHFFFAOYSA-N 0.000 claims 1
- NTOGTTYFZKYUPA-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]urea Chemical compound C1=C(NC=2OC(=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)NC1=CC=C(F)C=C1 NTOGTTYFZKYUPA-UHFFFAOYSA-N 0.000 claims 1
- KZFOFDORPQTDHN-UHFFFAOYSA-N 1-(4-methylphenyl)-3-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]urea Chemical compound C1=CC(C)=CC=C1NC(=O)NC1=CC=C(C)C(NC=2OC(=CN=2)C=2C=NC=CC=2)=C1 KZFOFDORPQTDHN-UHFFFAOYSA-N 0.000 claims 1
- MQERDMHSJBACBG-UHFFFAOYSA-N 1-[4-methyl-3-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl]-3-[3-(trifluoromethyl)phenyl]urea Chemical compound C1=C(NC=2OC(=CN=2)C=2C=CC=CC=2)C(C)=CC=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 MQERDMHSJBACBG-UHFFFAOYSA-N 0.000 claims 1
- XXCYDEXIHBWQBC-UHFFFAOYSA-N 1-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]-3-[4-(trifluoromethyl)phenyl]urea Chemical compound C1=C(NC=2OC(=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)NC1=CC=C(C(F)(F)F)C=C1 XXCYDEXIHBWQBC-UHFFFAOYSA-N 0.000 claims 1
- CGCLXYGIXNAGFW-UHFFFAOYSA-N 1-benzyl-3-[4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]thiourea Chemical compound C1=C(NC=2OC(=CN=2)C=2C=CN=CC=2)C(C)=CC=C1NC(=S)NCC1=CC=CC=C1 CGCLXYGIXNAGFW-UHFFFAOYSA-N 0.000 claims 1
- YSUBMVSDUMNSNS-UHFFFAOYSA-N 1-n-(1,3-benzoxazol-2-yl)-4-methyl-3-n-(5-pyridin-4-yl-1,3-oxazol-2-yl)benzene-1,3-diamine Chemical compound CC1=CC=C(NC=2OC3=CC=CC=C3N=2)C=C1NC(O1)=NC=C1C1=CC=NC=C1 YSUBMVSDUMNSNS-UHFFFAOYSA-N 0.000 claims 1
- AJWYELFDOXLJJR-UHFFFAOYSA-N 2-(2,4-difluorophenyl)-n-[4-methyl-3-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl]acetamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=CC=CC=2)C(C)=CC=C1NC(=O)CC1=CC=C(F)C=C1F AJWYELFDOXLJJR-UHFFFAOYSA-N 0.000 claims 1
- PWHUSSACDKSJEW-UHFFFAOYSA-N 2-(2,6-dichlorophenyl)-n-[4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]acetamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=CN=CC=2)C(C)=CC=C1NC(=O)CC1=C(Cl)C=CC=C1Cl PWHUSSACDKSJEW-UHFFFAOYSA-N 0.000 claims 1
- LBOHDXZQUHPFSL-UHFFFAOYSA-N 2-(3-bromophenyl)-n-[4-methyl-3-[(5-pyridin-2-yl-1,3-oxazol-2-yl)amino]phenyl]acetamide Chemical compound C1=C(NC=2OC(=CN=2)C=2N=CC=CC=2)C(C)=CC=C1NC(=O)CC1=CC=CC(Br)=C1 LBOHDXZQUHPFSL-UHFFFAOYSA-N 0.000 claims 1
- KEEBUCPGLVETKH-UHFFFAOYSA-N 2-(3-methylphenyl)-n-[4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]acetamide Chemical compound CC1=CC=CC(CC(=O)NC=2C=C(NC=3OC(=CN=3)C=3C=CN=CC=3)C(C)=CC=2)=C1 KEEBUCPGLVETKH-UHFFFAOYSA-N 0.000 claims 1
- NHNPJUHHBDTXMQ-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]acetamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)CC1=CC=C(F)C=C1 NHNPJUHHBDTXMQ-UHFFFAOYSA-N 0.000 claims 1
- MTDSANYYCBYFOZ-UHFFFAOYSA-N 2-cyano-n-[4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]acetamide Chemical compound CC1=CC=C(NC(=O)CC#N)C=C1NC1=NC=C(C=2C=CN=CC=2)O1 MTDSANYYCBYFOZ-UHFFFAOYSA-N 0.000 claims 1
- CBRSXJFHARVENS-UHFFFAOYSA-N 2-ethoxy-n-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]acetamide Chemical compound CCOCC(=O)NC1=CC=C(C)C(NC=2OC(=CN=2)C=2C=NC=CC=2)=C1 CBRSXJFHARVENS-UHFFFAOYSA-N 0.000 claims 1
- VMHVHLSOHUQGSO-UHFFFAOYSA-N 2-methylpropyl n-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]carbamate Chemical compound CC(C)COC(=O)NC1=CC=C(C)C(NC=2OC(=CN=2)C=2C=NC=CC=2)=C1 VMHVHLSOHUQGSO-UHFFFAOYSA-N 0.000 claims 1
- VCQMPUPEARTEGT-UHFFFAOYSA-N 2-methylpropyl n-[4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]carbamate Chemical compound CC(C)COC(=O)NC1=CC=C(C)C(NC=2OC(=CN=2)C=2C=CN=CC=2)=C1 VCQMPUPEARTEGT-UHFFFAOYSA-N 0.000 claims 1
- ONZFPAUTTVNGRO-UHFFFAOYSA-N 3,5-dimethoxy-n-[4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]benzamide Chemical compound COC1=CC(OC)=CC(C(=O)NC=2C=C(NC=3OC(=CN=3)C=3C=CN=CC=3)C(C)=CC=2)=C1 ONZFPAUTTVNGRO-UHFFFAOYSA-N 0.000 claims 1
- VBUDIOJRHSRDNE-UHFFFAOYSA-N 3-(4-fluorophenyl)-n-[4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]propanamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=CN=CC=2)C(C)=CC=C1NC(=O)CCC1=CC=C(F)C=C1 VBUDIOJRHSRDNE-UHFFFAOYSA-N 0.000 claims 1
- QQGKEUWTCWSWIM-UHFFFAOYSA-N 3-(dimethylamino)-n-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]benzamide Chemical compound CN(C)C1=CC=CC(C(=O)NC=2C=C(NC=3OC(=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=C1 QQGKEUWTCWSWIM-UHFFFAOYSA-N 0.000 claims 1
- CFSOZHKOFYGOJX-UHFFFAOYSA-N 3-bromo-n-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]benzamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(Br)=C1 CFSOZHKOFYGOJX-UHFFFAOYSA-N 0.000 claims 1
- IFZBJUUFHJRIQE-UHFFFAOYSA-N 3-fluoro-4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]benzamide Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3OC(=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1F IFZBJUUFHJRIQE-UHFFFAOYSA-N 0.000 claims 1
- IDXSLYWMIDHQFU-UHFFFAOYSA-N 3-methoxy-n-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]propanamide Chemical compound COCCC(=O)NC1=CC=C(C)C(NC=2OC(=CN=2)C=2C=NC=CC=2)=C1 IDXSLYWMIDHQFU-UHFFFAOYSA-N 0.000 claims 1
- FLSOCFCHSDCSMM-UHFFFAOYSA-N 4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]benzamide Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3OC(=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 FLSOCFCHSDCSMM-UHFFFAOYSA-N 0.000 claims 1
- QHAQNXJCRZHKRZ-UHFFFAOYSA-N 4-[3-(dimethylamino)propylamino]-n-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(NCCCN(C)C)=CC=C1C(=O)NC1=CC=C(C)C(NC=2OC(=CN=2)C=2C=NC=CC=2)=C1 QHAQNXJCRZHKRZ-UHFFFAOYSA-N 0.000 claims 1
- GQGBFHDLMSEMFF-UHFFFAOYSA-N 4-cyano-n-[4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]benzamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=CN=CC=2)C(C)=CC=C1NC(=O)C1=CC=C(C#N)C=C1 GQGBFHDLMSEMFF-UHFFFAOYSA-N 0.000 claims 1
- LUBJFLBNBALVMZ-UHFFFAOYSA-N 4-methyl-1-n-(5-phenyl-1,3,4-oxadiazol-2-yl)-3-n-(5-pyridin-4-yl-1,3-oxazol-2-yl)benzene-1,3-diamine Chemical compound C1=C(NC=2OC(=CN=2)C=2C=CN=CC=2)C(C)=CC=C1NC(O1)=NN=C1C1=CC=CC=C1 LUBJFLBNBALVMZ-UHFFFAOYSA-N 0.000 claims 1
- LLRWNDWHVNPUMJ-UHFFFAOYSA-N 4-methyl-1-n-(5-phenyl-1,3-oxazol-2-yl)-3-n-(5-pyridin-4-yl-1,3-oxazol-2-yl)benzene-1,3-diamine Chemical compound C1=C(NC=2OC(=CN=2)C=2C=CN=CC=2)C(C)=CC=C1NC(O1)=NC=C1C1=CC=CC=C1 LLRWNDWHVNPUMJ-UHFFFAOYSA-N 0.000 claims 1
- CBOXAKYSTSFXTD-UHFFFAOYSA-N 4-methyl-1-n-(5-pyridin-3-yl-1,3-oxazol-2-yl)-3-n-(5-pyridin-4-yl-1,3-oxazol-2-yl)benzene-1,3-diamine Chemical compound C1=C(NC=2OC(=CN=2)C=2C=CN=CC=2)C(C)=CC=C1NC(O1)=NC=C1C1=CC=CN=C1 CBOXAKYSTSFXTD-UHFFFAOYSA-N 0.000 claims 1
- TXHCAUUNNPYFJD-UHFFFAOYSA-N 4-methyl-n-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]pentanamide Chemical compound CC(C)CCC(=O)NC1=CC=C(C)C(NC=2OC(=CN=2)C=2C=NC=CC=2)=C1 TXHCAUUNNPYFJD-UHFFFAOYSA-N 0.000 claims 1
- CEUWQPLATDRHEL-UHFFFAOYSA-N 4-n-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]benzene-1,4-dicarboxamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)C1=CC=C(C(N)=O)C=C1 CEUWQPLATDRHEL-UHFFFAOYSA-N 0.000 claims 1
- LGZSXFUMYWZFGV-UHFFFAOYSA-N 5-methyl-n-[4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]-1,2-oxazole-4-carboxamide Chemical compound O1N=CC(C(=O)NC=2C=C(NC=3OC(=CN=3)C=3C=CN=CC=3)C(C)=CC=2)=C1C LGZSXFUMYWZFGV-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010049153 Allergic sinusitis Diseases 0.000 claims 1
- 208000028185 Angioedema Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Natural products CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 206010015226 Erythema nodosum Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010061217 Infestation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010036030 Polyarthritis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000032384 Severe immune-mediated enteropathy Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- OYNHMJOHYYXABZ-UHFFFAOYSA-N [4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]-morpholin-4-ylmethanone Chemical compound CC1=CC=C(C(=O)N2CCOCC2)C=C1NC(O1)=NC=C1C1=CC=NC=C1 OYNHMJOHYYXABZ-UHFFFAOYSA-N 0.000 claims 1
- SGKCMBLBWJQZDX-UHFFFAOYSA-N [4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]-piperazin-1-ylmethanone Chemical compound CC1=CC=C(C(=O)N2CCNCC2)C=C1NC(O1)=NC=C1C1=CC=NC=C1 SGKCMBLBWJQZDX-UHFFFAOYSA-N 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000002052 anaphylactic effect Effects 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000001974 autoimmune enteropathy Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000006512 mast cell neoplasm Diseases 0.000 claims 1
- 208000006971 mastocytoma Diseases 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- RIAYRNVHQWZIBD-UHFFFAOYSA-N methyl 4-[[4-methyl-3-[(4-pyridin-3-yl-1,3-oxazol-2-yl)amino]anilino]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CNC1=CC=C(C)C(NC=2OC=C(N=2)C=2C=NC=CC=2)=C1 RIAYRNVHQWZIBD-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- HOWLHUUPCSMTAZ-UHFFFAOYSA-N n-(3-chlorophenyl)-4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]benzamide Chemical compound CC1=CC=C(C(=O)NC=2C=C(Cl)C=CC=2)C=C1NC(O1)=NC=C1C1=CC=CN=C1 HOWLHUUPCSMTAZ-UHFFFAOYSA-N 0.000 claims 1
- VZXNYEPZQACYHR-UHFFFAOYSA-N n-(3-fluoro-4-methylphenyl)-4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]benzamide Chemical compound C1=C(F)C(C)=CC=C1NC(=O)C1=CC=C(C)C(NC=2OC(=CN=2)C=2C=CN=CC=2)=C1 VZXNYEPZQACYHR-UHFFFAOYSA-N 0.000 claims 1
- BLAFNVLTEJJENP-UHFFFAOYSA-N n-(4-cyanophenyl)-4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]benzamide Chemical compound CC1=CC=C(C(=O)NC=2C=CC(=CC=2)C#N)C=C1NC(O1)=NC=C1C1=CC=CN=C1 BLAFNVLTEJJENP-UHFFFAOYSA-N 0.000 claims 1
- VZYBLENJMIDDAE-UHFFFAOYSA-N n-(4-fluorophenyl)-2-[4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]acetamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=CN=CC=2)C(C)=CC=C1CC(=O)NC1=CC=C(F)C=C1 VZYBLENJMIDDAE-UHFFFAOYSA-N 0.000 claims 1
- IPIWTZUPUBHJCL-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]-4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]benzamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(C)C(NC=2OC(=CN=2)C=2C=CN=CC=2)=C1 IPIWTZUPUBHJCL-UHFFFAOYSA-N 0.000 claims 1
- OVSPCJDMIPJNHX-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]benzamide Chemical compound CN(C)CCNC(=O)C1=CC=C(C)C(NC=2OC(=CN=2)C=2C=NC=CC=2)=C1 OVSPCJDMIPJNHX-UHFFFAOYSA-N 0.000 claims 1
- URDAADWEIKUUPU-UHFFFAOYSA-N n-[3-(dimethylamino)phenyl]-4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]benzamide Chemical compound CN(C)C1=CC=CC(NC(=O)C=2C=C(NC=3OC(=CN=3)C=3C=CN=CC=3)C(C)=CC=2)=C1 URDAADWEIKUUPU-UHFFFAOYSA-N 0.000 claims 1
- WHKFRFKKQRZOAM-UHFFFAOYSA-N n-[3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)NC=2C=C(NC=3OC(=CN=3)C=3C=NC=CC=3)C=CC=2)=C1 WHKFRFKKQRZOAM-UHFFFAOYSA-N 0.000 claims 1
- CEATXLYGLKXKBX-UHFFFAOYSA-N n-[3-[[5-(4-cyanophenyl)-1,3-oxazol-2-yl]amino]-4-methylphenyl]-2-(2,4-difluorophenyl)acetamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=CC(=CC=2)C#N)C(C)=CC=C1NC(=O)CC1=CC=C(F)C=C1F CEATXLYGLKXKBX-UHFFFAOYSA-N 0.000 claims 1
- ODUIXQCTCFZYAW-UHFFFAOYSA-N n-[4-chloro-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)NC=2C=C(NC=3OC(=CN=3)C=3C=NC=CC=3)C(Cl)=CC=2)=C1 ODUIXQCTCFZYAW-UHFFFAOYSA-N 0.000 claims 1
- RFBZLUWAOIJRQR-UHFFFAOYSA-N n-[4-fluoro-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=NC=CC=2)C(F)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 RFBZLUWAOIJRQR-UHFFFAOYSA-N 0.000 claims 1
- MZMBQVYIUHWTHE-UHFFFAOYSA-N n-[4-methoxy-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=NC=CC=2)C(OC)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 MZMBQVYIUHWTHE-UHFFFAOYSA-N 0.000 claims 1
- XIZNQJMQUBYUJV-UHFFFAOYSA-N n-[4-methoxy-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]-2-[4-(trifluoromethyl)phenyl]acetamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=CN=CC=2)C(OC)=CC=C1NC(=O)CC1=CC=C(C(F)(F)F)C=C1 XIZNQJMQUBYUJV-UHFFFAOYSA-N 0.000 claims 1
- WLZKZWONUFPREG-UHFFFAOYSA-N n-[4-methyl-3-[(4-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2OC=C(N=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 WLZKZWONUFPREG-UHFFFAOYSA-N 0.000 claims 1
- NTDCCVFLWYRGDH-UHFFFAOYSA-N n-[4-methyl-3-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=CC=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 NTDCCVFLWYRGDH-UHFFFAOYSA-N 0.000 claims 1
- YUENBBXFAOPQMB-UHFFFAOYSA-N n-[4-methyl-3-[(5-pyridin-2-yl-1,3-oxazol-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2OC(=CN=2)C=2N=CC=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 YUENBBXFAOPQMB-UHFFFAOYSA-N 0.000 claims 1
- MBXJCNACGQESRD-UHFFFAOYSA-N n-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]-2-piperazin-1-ylacetamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)CN1CCNCC1 MBXJCNACGQESRD-UHFFFAOYSA-N 0.000 claims 1
- MGFIEQNFVMOMCT-UHFFFAOYSA-N n-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]-3-piperazin-1-ylpropanamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)CCN1CCNCC1 MGFIEQNFVMOMCT-UHFFFAOYSA-N 0.000 claims 1
- AKSBWJDDDZFYCO-UHFFFAOYSA-N n-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]-3-pyrrolidin-1-ylpropanamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)CCN1CCCC1 AKSBWJDDDZFYCO-UHFFFAOYSA-N 0.000 claims 1
- WTHMHBCPQRFUBK-UHFFFAOYSA-N n-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]acetamide Chemical compound CC(=O)NC1=CC=C(C)C(NC=2OC(=CN=2)C=2C=NC=CC=2)=C1 WTHMHBCPQRFUBK-UHFFFAOYSA-N 0.000 claims 1
- ATUHBPRJSKGSQK-UHFFFAOYSA-N n-[4-methyl-3-[(5-pyridin-3-yl-1,3-oxazol-2-yl)amino]phenyl]pyridine-4-carboxamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)C1=CC=NC=C1 ATUHBPRJSKGSQK-UHFFFAOYSA-N 0.000 claims 1
- PVWWBTNRVDVQIP-UHFFFAOYSA-N n-[4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]-1-phenylmethanesulfonamide Chemical compound C1=C(NC=2OC(=CN=2)C=2C=CN=CC=2)C(C)=CC=C1NS(=O)(=O)CC1=CC=CC=C1 PVWWBTNRVDVQIP-UHFFFAOYSA-N 0.000 claims 1
- FDAHBOFXYSTPOL-UHFFFAOYSA-N n-[4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]-1h-indole-6-carboxamide Chemical compound CC1=CC=C(NC(=O)C=2C=C3NC=CC3=CC=2)C=C1NC(O1)=NC=C1C1=CC=NC=C1 FDAHBOFXYSTPOL-UHFFFAOYSA-N 0.000 claims 1
- FOMPQOZSGBLQMX-UHFFFAOYSA-N n-[4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]phenyl]-3-propan-2-yloxybenzamide Chemical compound CC(C)OC1=CC=CC(C(=O)NC=2C=C(NC=3OC(=CN=3)C=3C=CN=CC=3)C(C)=CC=2)=C1 FOMPQOZSGBLQMX-UHFFFAOYSA-N 0.000 claims 1
- HORDAYGVVWNPQO-UHFFFAOYSA-N n-benzyl-4-methyl-3-[(5-pyridin-4-yl-1,3-oxazol-2-yl)amino]benzamide Chemical compound CC1=CC=C(C(=O)NCC=2C=CC=CC=2)C=C1NC(O1)=NC=C1C1=CC=NC=C1 HORDAYGVVWNPQO-UHFFFAOYSA-N 0.000 claims 1
- 230000002956 necrotizing effect Effects 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000030428 polyarticular arthritis Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 206010036784 proctocolitis Diseases 0.000 claims 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 230000009897 systematic effect Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 abstract 1
- 208000031295 Animal disease Diseases 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 abstract 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51321403P | 2003-10-23 | 2003-10-23 | |
PCT/IB2004/003698 WO2005040139A2 (en) | 2003-10-23 | 2004-10-22 | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100326T1 true HRP20100326T1 (hr) | 2010-10-31 |
Family
ID=42827352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100326T HRP20100326T1 (hr) | 2003-10-23 | 2010-06-07 | 2-aminoariloksazolni spojevi kao inhibitori tirozinske kinaze |
Country Status (16)
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7992643B2 (en) | 2003-05-31 | 2011-08-09 | Cameron Systems (Ireland) Limited | Apparatus and method for recovering fluids from a well and/or injecting fluids into a well |
ATE439837T1 (de) * | 2003-06-03 | 2009-09-15 | Novartis Ag | 5-gliedrige heterocyclische p-38 inhibitoren |
CN1950347B (zh) * | 2003-10-23 | 2012-04-04 | Ab科学公司 | 作为酪氨酸激酶抑制剂的2-氨基芳基噁唑化合物 |
US8066076B2 (en) | 2004-02-26 | 2011-11-29 | Cameron Systems (Ireland) Limited | Connection system for subsea flow interface equipment |
EP1755592A1 (en) * | 2004-04-20 | 2007-02-28 | AB Science | Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy |
WO2005102318A1 (en) * | 2004-04-20 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating hiv related diseases |
JP2007538064A (ja) * | 2004-05-18 | 2007-12-27 | アブ サイエンス | 化学または生物兵器に曝露された患者を処置するための肥満細胞阻害剤の使用法 |
WO2005115385A1 (en) * | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
US20080242704A1 (en) * | 2005-04-04 | 2008-10-02 | Ab Science | Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors |
US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
EP1904065A2 (en) * | 2005-07-14 | 2008-04-02 | AB Science | Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma |
WO2007076460A2 (en) * | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Substituted thiazole ureas useful as inhibitors of protein kinases |
ES2389678T3 (es) * | 2006-04-20 | 2012-10-30 | Janssen Pharmaceutica Nv | Un inhibidor de la quinasa C-Kit para su uso en el tratamiento de tumores del estroma gastrointestinal o mastocitosis |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
ES2565238T3 (es) | 2006-04-20 | 2016-04-01 | Janssen Pharmaceutica N.V. | Inhibidores de la c-fms quinasa |
PT2021335E (pt) | 2006-04-20 | 2011-07-25 | Janssen Pharmaceutica Nv | Compostos heterocíclicos como inibidores de c-fms quinase |
GB0618001D0 (en) | 2006-09-13 | 2006-10-18 | Des Enhanced Recovery Ltd | Method |
US7790756B2 (en) * | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
GB0625191D0 (en) | 2006-12-18 | 2007-01-24 | Des Enhanced Recovery Ltd | Apparatus and method |
GB0625526D0 (en) | 2006-12-18 | 2007-01-31 | Des Enhanced Recovery Ltd | Apparatus and method |
EP2117531B1 (en) | 2007-01-12 | 2016-11-02 | AB Science | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors |
GB0701426D0 (en) * | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
FR2928150A1 (fr) * | 2008-02-29 | 2009-09-04 | Vetoquinol Sa Sa | Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens |
EP2145891A1 (en) * | 2008-07-09 | 2010-01-20 | Vetoquinol S.A. | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
EP2519517B1 (en) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
EP2680846A4 (en) * | 2011-03-01 | 2014-08-06 | Npharmakon Llc | USE OF N- (4-METHOXYPHENYL) -1-PHENYL-1H-PYRAZOL-3-AMINE AND COMPOUNDS ASSOCIATED THEREWITH |
US8551992B2 (en) | 2011-05-27 | 2013-10-08 | Neosome Life Sciences, LLC | Aminooxazole inhibitors of cyclin dependent kinases |
MX2014001079A (es) * | 2011-07-27 | 2014-09-12 | Ab Science | Derivados de oxazoly tiazol como inhibidores de la proteina quinasa selectiva (c-kit). |
GB201202027D0 (en) | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
EP2634185B1 (en) | 2012-03-02 | 2016-01-13 | Sareum Limited | TYK2 kinase inhibitors |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
US9303046B2 (en) | 2012-08-07 | 2016-04-05 | Janssen Pharmaceutica Nv | Process for the preparation of heterocyclic ester derivatives |
US20160175302A1 (en) * | 2014-12-17 | 2016-06-23 | Ab Science | Masitinib for treating gastric cancer |
EP3053920B1 (en) * | 2015-02-05 | 2020-04-08 | AB Science | Compounds with anti-tumoral activity |
US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
EP4019515A1 (en) * | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
WO2021047677A1 (zh) * | 2019-09-12 | 2021-03-18 | 中国科学院上海药物研究所 | 一类irak4激酶抑制剂及其制备和应用 |
EP4200167A1 (en) * | 2020-08-21 | 2023-06-28 | Pylon Manufacturing Corp. | Windshield wiper blade |
CN113185511B (zh) * | 2021-05-24 | 2022-04-26 | 中国医学科学院医药生物技术研究所 | 一种嘧啶类化合物及其制备方法和应用 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3740420A (en) * | 1967-11-28 | 1973-06-19 | Crown Zellerbach Corp | Pharmaceutical compositions with dimethyl sulfoxide |
FR2077803B1 (US08110591-20120207-C00078.png) * | 1970-02-16 | 1973-03-16 | Innothera Lab Sa | |
US3743727A (en) * | 1970-11-16 | 1973-07-03 | Crown Zellerbach Corp | Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide |
US4405616A (en) * | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
US3989816A (en) * | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
US4343940A (en) * | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
CA1163561A (en) * | 1979-11-06 | 1984-03-13 | Cyril Boroda | Preparation containing nitroglycerine and optionally other medicaments and preparation thereof |
US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4460372A (en) * | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
US4411893A (en) * | 1981-08-14 | 1983-10-25 | Minnesota Mining And Manufacturing Company | Topical medicament preparations |
CA1236029A (en) * | 1984-05-14 | 1988-05-03 | Edmund Sandborn | Pharmaceutical solutions comprising dimethyl sulfoxide |
US4615699A (en) * | 1985-05-03 | 1986-10-07 | Alza Corporation | Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes |
US5000775A (en) | 1985-12-31 | 1991-03-19 | Monsanto Company | 2-amino-4,5-disubstituted-oxazole/thiazole compounds as herbicide antidotes |
JPH0651679B2 (ja) * | 1986-07-21 | 1994-07-06 | 株式会社大塚製薬工場 | p−アミノフェノ−ル誘導体 |
US4868183A (en) | 1986-07-21 | 1989-09-19 | Otsuka Pharmaceutical Factory, Inc. | N-pyrazinyl substituted P-aminophenols |
US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
CA2078214C (en) | 1990-04-02 | 1995-03-28 | Robert Lee Dow | Benzylphosphonic acid tyrosine kinase inhibitors |
US5302606A (en) * | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
DK0584222T3 (da) | 1991-05-10 | 1998-02-23 | Rhone Poulenc Rorer Int | Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5714493A (en) * | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
CA2108889A1 (en) | 1991-05-29 | 1992-11-30 | Robert Lee Dow | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
US5213453A (en) | 1991-06-28 | 1993-05-25 | Tapmatic Corporation | Cooling systems in tapping attachments suitable for high pressure applications |
GB9121418D0 (en) * | 1991-10-09 | 1991-11-20 | Nader Esfahani Rahim | Imaginograph |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
RU2155187C2 (ru) | 1992-08-06 | 2000-08-27 | Варнер-Ламберт Компани | Производные индола, их таутомеры, смеси их изомеров или отдельные изомеры и фармацевтически приемлемые соли, фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозинкиназу активностью и способ торможения зависящего от протеин-тирозинкиназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека. |
US5330992A (en) * | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US5656643A (en) * | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5906202A (en) * | 1996-11-21 | 1999-05-25 | Aradigm Corporation | Device and method for directing aerosolized mist to a specific area of the respiratory tract |
PL334304A1 (en) * | 1996-12-24 | 2000-02-14 | Chugai Pharmaceutical Co Ltd | Derivatives of aromatic amines acting as nos inhibitors |
JPH10237028A (ja) * | 1996-12-24 | 1998-09-08 | Chugai Pharmaceut Co Ltd | Nos阻害作用を有する芳香族アミン誘導体 |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
US6596747B2 (en) * | 1998-10-29 | 2003-07-22 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
WO2000025780A1 (en) * | 1998-10-29 | 2000-05-11 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of impdh enzyme |
IL143920A0 (en) | 1998-12-31 | 2002-04-21 | Sugen Inc | 3-heteroarylidenyl-2-indolinone derivatives and pharmaceutical compositions containing the same |
US20020137755A1 (en) * | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
US7700610B2 (en) | 2001-06-29 | 2010-04-20 | Ab Science | Use of tyrosine kinase inhibitors for treating allergic diseases |
US20030091974A1 (en) | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
JP2005502614A (ja) | 2001-06-29 | 2005-01-27 | アブ サイエンス | 多発性硬化症(ms)を治療するためのチロシンキナーゼ阻害剤の使用方法 |
JP2004537537A (ja) | 2001-06-29 | 2004-12-16 | アブ サイエンス | 炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法 |
EP1401411A2 (en) | 2001-06-29 | 2004-03-31 | AB Science | Use of tyrosine kinase inhibitors for treating bone loss |
US7678805B2 (en) | 2001-06-29 | 2010-03-16 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD) |
EP1401429A2 (en) | 2001-06-29 | 2004-03-31 | AB Science | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
ATE376182T1 (de) | 2001-06-29 | 2007-11-15 | Ab Science | C-kit inhibitoren |
JP2004530730A (ja) | 2001-06-29 | 2004-10-07 | アブ サイエンス | 腫瘍の血管新生を治療するための強力で選択的かつ非毒性のc−kit阻害剤の使用法 |
JP2004536097A (ja) | 2001-06-29 | 2004-12-02 | アブ サイエンス | 自己免疫疾患を治療するためのチロシンキナーゼ阻害剤の使用法 |
US20040242612A1 (en) | 2001-09-20 | 2004-12-02 | Alain Moussy | Use of tyrosine kinase inhibitors for promoting hair growth |
DE60225590T2 (de) | 2001-09-20 | 2008-09-25 | Ab Science | C-kithemmer zur behandlung von bakteriellen infektionen |
JP2005511596A (ja) | 2001-09-20 | 2005-04-28 | アブ サイエンス | ヒトの皮膚を白くし、且つメラノサイト機能不全関連疾病を治療するためのチロシンキナーゼ阻害剤の使用方法 |
WO2003072090A2 (en) | 2002-02-27 | 2003-09-04 | Ab Science | Use of tyrosine kinase inhibitors for treating cns disorders |
WO2003072106A2 (en) | 2002-02-27 | 2003-09-04 | Ab Science | Use of tyrosine kinase inhibitors for treating substance use disorders |
TW200401638A (en) | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
AU2003287178A1 (en) * | 2002-10-10 | 2004-05-04 | Smithkline Beecham Corporation | Chemical compounds |
JP2006519220A (ja) | 2003-02-27 | 2006-08-24 | アブ サイエンス | 異なる型の肥満細胞症に適合可能なテイラーメイド治療方法 |
ATE439837T1 (de) * | 2003-06-03 | 2009-09-15 | Novartis Ag | 5-gliedrige heterocyclische p-38 inhibitoren |
CN1829513A (zh) * | 2003-06-03 | 2006-09-06 | 诺瓦提斯公司 | 基于五元杂环的p-38抑制剂 |
CN1950347B (zh) * | 2003-10-23 | 2012-04-04 | Ab科学公司 | 作为酪氨酸激酶抑制剂的2-氨基芳基噁唑化合物 |
-
2004
- 2004-10-22 CN CN2004800371595A patent/CN1950347B/zh not_active Expired - Fee Related
- 2004-10-22 PL PL04791783T patent/PL1684750T3/pl unknown
- 2004-10-22 DK DK04791783.6T patent/DK1684750T3/da active
- 2004-10-22 JP JP2006536215A patent/JP4971797B2/ja not_active Expired - Fee Related
- 2004-10-22 EP EP04791783A patent/EP1684750B1/en active Active
- 2004-10-22 US US10/576,267 patent/US7718676B2/en not_active Expired - Fee Related
- 2004-10-22 WO PCT/IB2004/003698 patent/WO2005040139A2/en active Application Filing
- 2004-10-22 BR BRPI0415467-3A patent/BRPI0415467A/pt not_active IP Right Cessation
- 2004-10-22 NZ NZ546645A patent/NZ546645A/en not_active IP Right Cessation
- 2004-10-22 AU AU2004283162A patent/AU2004283162B2/en not_active Ceased
- 2004-10-22 AT AT04791783T patent/ATE465731T1/de active
- 2004-10-22 CA CA2542909A patent/CA2542909C/en not_active Expired - Fee Related
-
2006
- 2006-04-20 IL IL175028A patent/IL175028A/en not_active IP Right Cessation
- 2006-05-22 NO NO20062308A patent/NO20062308L/no not_active Application Discontinuation
- 2006-11-01 HK HK06111993.8A patent/HK1091134A1/xx not_active IP Right Cessation
-
2010
- 2010-01-11 US US12/654,957 patent/US8110591B2/en not_active Expired - Fee Related
- 2010-06-07 HR HR20100326T patent/HRP20100326T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
NZ546645A (en) | 2010-02-26 |
NO20062308L (no) | 2006-05-22 |
EP1684750A2 (en) | 2006-08-02 |
US20070142390A1 (en) | 2007-06-21 |
CA2542909C (en) | 2012-07-10 |
PL1684750T3 (pl) | 2010-10-29 |
WO2005040139A3 (en) | 2005-10-13 |
IL175028A0 (en) | 2006-08-20 |
BRPI0415467A (pt) | 2006-12-19 |
AU2004283162A1 (en) | 2005-05-06 |
US20100113471A1 (en) | 2010-05-06 |
CN1950347A (zh) | 2007-04-18 |
CN1950347B (zh) | 2012-04-04 |
WO2005040139A8 (en) | 2006-06-01 |
AU2004283162B2 (en) | 2011-12-15 |
IL175028A (en) | 2011-02-28 |
HK1091134A1 (en) | 2007-01-12 |
JP2007509130A (ja) | 2007-04-12 |
US7718676B2 (en) | 2010-05-18 |
US8110591B2 (en) | 2012-02-07 |
JP4971797B2 (ja) | 2012-07-11 |
EP1684750B1 (en) | 2010-04-28 |
WO2005040139A2 (en) | 2005-05-06 |
DK1684750T3 (da) | 2010-08-09 |
CA2542909A1 (en) | 2005-05-06 |
ATE465731T1 (de) | 2010-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100326T1 (hr) | 2-aminoariloksazolni spojevi kao inhibitori tirozinske kinaze | |
JP2007509130A5 (US08110591-20120207-C00078.png) | ||
KR101036866B1 (ko) | 2-(3-아미노아릴)아미노-4-아릴-티아졸 및 c-kit억제제로서의 이의 용도 | |
JP5204643B2 (ja) | 置換オキサゾール誘導体、およびチロシンキナーゼ阻害薬としてのそれらの使用 | |
ZA200604041B (en) | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors | |
KR20060129413A (ko) | 티로신 키나제 억제제로서의2-(3-치환된-아릴)아미노-4-아릴-티아졸 | |
WO2006064375A9 (en) | Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases | |
HRP20220314T1 (hr) | Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao plazma kallikrein inhibitori | |
MXPA06004581A (en) | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors | |
MXPA06008597A (en) | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors |